Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
Weibull
longevity
non-proportional hazards
proportional time
relative time
time-to-event
Journal
Biometrical journal. Biometrische Zeitschrift
ISSN: 1521-4036
Titre abrégé: Biom J
Pays: Germany
ID NLM: 7708048
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
23
01
2021
received:
10
02
2020
accepted:
14
03
2021
pubmed:
18
7
2021
medline:
3
11
2021
entrez:
17
7
2021
Statut:
ppublish
Résumé
Sample size calculations for two-arm clinical trials with a time-to-event endpoint have traditionally used the assumption of proportional hazards (PH) or the assumption of exponentially distributed survival times. Available software provides methods for sample size calculation using a nonparametric logrank test, Schoenfeld's formula for Cox PH model, or parametric calculations specific to the exponential distribution. In cases where the PH assumption is not valid, the first-choice method is to compute sample size assuming a piecewise linear survival curve (Lakatos approach) for both the control and treatment arms with judiciously chosen cut-points. Recent advances in literature have used the assumption of Weibull distributed times for single-arm trials, and, newer methods have emerged that allow sample size calculations for two-arm trials using the assumption of proportional time (PT) while considering non-PH. These methods, however, always assume an instantaneous effect of treatment relative to control requiring that the effect size be defined by a single number whose magnitude is preserved throughout the trial duration. Here, we consider the scenarios where the hypothesized benefit of treatment relative to control may not be constant giving rise to the notion of Relative Time (RT). By assuming that survival times for control and treatment arm come from two different Weibull distributions with different location and shape parameters, we develop the methodology for sample size calculation for specific cases of both non-PH and non-PT. Simulations are conducted to assess the operation characteristics of the proposed method and a practical example is discussed.
Identifiants
pubmed: 34272897
doi: 10.1002/bimj.202000043
pmc: PMC8497393
mid: NIHMS1716042
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1406-1433Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002366
Pays : United States
Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
Stat Med. 1982 Apr-Jun;1(2):121-9
pubmed: 7187087
Contemp Clin Trials Commun. 2020 Feb 26;17:100548
pubmed: 32154431
Biometrics. 1983 Jun;39(2):499-503
pubmed: 6354290
Biometrics. 2016 Mar;72(1):215-21
pubmed: 26302239
Lifetime Data Anal. 2017 Apr;23(2):254-274
pubmed: 26832911
Stat Med. 1992 Jan 30;11(2):179-91
pubmed: 1579757
Pharm Stat. 2015 Jan-Feb;14(1):26-33
pubmed: 25339496
J Am Coll Cardiol. 2019 Oct 22;74(16):2102-2112
pubmed: 31623769
Biometrics. 1986 Sep;42(3):507-19
pubmed: 3567285
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Stat Med. 2019 Sep 10;38(20):3782-3790
pubmed: 31131462
Pharm Stat. 2017 Jan;16(1):87-94
pubmed: 27860138
Stat Med. 2017 Nov 20;36(26):4121-4140
pubmed: 28815655
Stat Med. 2007 Oct 15;26(23):4352-74
pubmed: 17342754
Contemp Clin Trials Commun. 2019 Apr 13;15:100360
pubmed: 31080909
Biometrics. 1988 Mar;44(1):229-41
pubmed: 3358991
Stat Med. 2012 Dec 20;31(29):3959-71
pubmed: 22786805
Control Clin Trials. 2000 Dec;21(6):552-60
pubmed: 11146149
Pharm Stat. 2019 May;18(3):287-303
pubmed: 30592138
BMC Med Res Methodol. 2013 Dec 07;13:152
pubmed: 24314264